(Q44368440)

2 December 2017

0 references

Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome (English)

1 reference

2 December 2017

1 reference

Christie M. Ballantyne

1

object named as

Christie M Ballantyne

1 reference

2 December 2017

Evan A Stein

2

1 reference

2 December 2017

Rodolfo Paoletti

3

1 reference

2 December 2017

Harry Southworth

4

1 reference

2 December 2017

James W Blasetto

5

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

American Journal of Cardiology

2 December 2017

published in

1 reference

2 December 2017

volume

91

1 reference

2 December 2017

issue

5A

1 reference

2 December 2017

page(s)

25C-27C; discussion 28C

1 reference

Banting lecture 1988. Role of insulin resistance in human disease

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Kelly West Lecture 1991. Challenges in diabetes epidemiology--from West to the rest

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Cardiovascular morbidity and mortality associated with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Waist circumference as a measure for indicating need for weight management.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

The US National Cholesterol Education Program. Adult treatment guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900006-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(03)00006-7

1 reference

2 December 2017

1 reference